New drug cocktails tested in battle against advanced head and neck cancer

NCT ID NCT06062420

Summary

This study is testing new combinations of immunotherapy drugs for people with advanced head and neck cancer that has returned or spread. It aims to see if these new combinations work better and are as safe as a single existing immunotherapy drug. The trial will enroll about 316 adults whose cancer tests positive for a specific marker (PD-L1) and who haven't had prior immunotherapy for their advanced disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS, HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    New Haven, Connecticut, 06511, United States

  • GSK Investigational Site

    Iowa City, Iowa, 52242, United States

  • GSK Investigational Site

    St Louis, Missouri, 63021, United States

  • GSK Investigational Site

    Columbus, Ohio, 43210, United States

  • GSK Investigational Site

    Milwaukee, Wisconsin, 53226, United States

  • GSK Investigational Site

    Buenos Aires, C1426ABP, Argentina

  • GSK Investigational Site

    Capital Federal, C1181ACH, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, C1056ABI, Argentina

  • GSK Investigational Site

    Córdoba, 5000, Argentina

  • GSK Investigational Site

    Florida, B1602DQD, Argentina

  • GSK Investigational Site

    Mendoza, M5500AYB, Argentina

  • GSK Investigational Site

    San Juan, 5400, Argentina

  • GSK Investigational Site

    Santa Fe, 3000, Argentina

  • GSK Investigational Site

    Santo André, 09060-650, Brazil

  • GSK Investigational Site

    São Paulo, 01221-020, Brazil

  • GSK Investigational Site

    São Paulo, 01246-000, Brazil

  • GSK Investigational Site

    Calgary, Alberta, T2N 5G2, Canada

  • GSK Investigational Site

    Edmonton, Alberta, T6G 1Z2, Canada

  • GSK Investigational Site

    Toronto, Ontario, M4N 3M5, Canada

  • GSK Investigational Site

    Toronto, Ontario, M5G 2M9, Canada

  • GSK Investigational Site

    Montreal, Quebec, H3T 1E2, Canada

  • GSK Investigational Site

    Herlev, Denmark

  • GSK Investigational Site

    Turku, 20520, Finland

  • GSK Investigational Site

    Bordeaux, 33075, France

  • GSK Investigational Site

    Caen, 14075, France

  • GSK Investigational Site

    Marseille, 13005, France

  • GSK Investigational Site

    Paris, 75005, France

  • GSK Investigational Site

    Rouen, 76038, France

  • GSK Investigational Site

    Villejuif, 94805, France

  • GSK Investigational Site

    Aachen, 52074, Germany

  • GSK Investigational Site

    Berlin, 12200, Germany

  • GSK Investigational Site

    Essen, 45122, Germany

  • GSK Investigational Site

    Frankfurt, 60488, Germany

  • GSK Investigational Site

    Giessen, 35392, Germany

  • GSK Investigational Site

    Hamburg, 20246, Germany

  • GSK Investigational Site

    Leipzig, 04103, Germany

  • GSK Investigational Site

    Regensburg, 93053, Germany

  • GSK Investigational Site

    Ulm, 89075, Germany

  • GSK Investigational Site

    Haidari - Athens, 12462, Greece

  • GSK Investigational Site

    Marousi, Greece

  • GSK Investigational Site

    Thessaloniki, 55236, Greece

  • GSK Investigational Site

    Győr, 9024, Hungary

  • GSK Investigational Site

    Kecskemét, 6000, Hungary

  • GSK Investigational Site

    Pécs, 7624, Hungary

  • GSK Investigational Site

    Bari, 70124, Italy

  • GSK Investigational Site

    Bologna, 40139, Italy

  • GSK Investigational Site

    Florence, 50134, Italy

  • GSK Investigational Site

    Genova, 16132, Italy

  • GSK Investigational Site

    Milan, 20133, Italy

  • GSK Investigational Site

    Naples, 80131, Italy

  • GSK Investigational Site

    Novara, 28100, Italy

  • GSK Investigational Site

    Padua, 35128, Italy

  • GSK Investigational Site

    Roma, 00144, Italy

  • GSK Investigational Site

    Roma, 00168, Italy

  • GSK Investigational Site

    Rozzano MI, 20089, Italy

  • GSK Investigational Site

    Aichi, 464-8681, Japan

  • GSK Investigational Site

    Chiba, 277-8577, Japan

  • GSK Investigational Site

    Hyōgo, 650-0017, Japan

  • GSK Investigational Site

    Osaka, 541-8567, Japan

  • GSK Investigational Site

    Saitama, 350-1298, Japan

  • GSK Investigational Site

    Shizuoka, 411-8777, Japan

  • GSK Investigational Site

    Tokyo, 104-0045, Japan

  • GSK Investigational Site

    Oslo, 0379, Norway

  • GSK Investigational Site

    Bielsko-Biala, 43-300, Poland

  • GSK Investigational Site

    Gliwice, 44-102, Poland

  • GSK Investigational Site

    Katowice, 40-514, Poland

  • GSK Investigational Site

    Krakow, 31-826, Poland

  • GSK Investigational Site

    Przemyśl, 37-700, Poland

  • GSK Investigational Site

    Siedlce, 08-110, Poland

  • GSK Investigational Site

    Warsaw, 04-141, Poland

  • GSK Investigational Site

    Almada, 2801-951, Portugal

  • GSK Investigational Site

    Lisbon, 1649-035, Portugal

  • GSK Investigational Site

    Porto, 4099-001, Portugal

  • GSK Investigational Site

    Porto, 4200-072, Portugal

  • GSK Investigational Site

    Brasov, 500283, Romania

  • GSK Investigational Site

    Bucharest, 020142, Romania

  • GSK Investigational Site

    Bucharest, 022328, Romania

  • GSK Investigational Site

    Bucharest, 030171, Romania

  • GSK Investigational Site

    Bucharest, 30463, Romania

  • GSK Investigational Site

    Craiova, 200542, Romania

  • GSK Investigational Site

    Floreşti, 407280, Romania

  • GSK Investigational Site

    Iași, 700483, Romania

  • GSK Investigational Site

    Oradea, 410469, Romania

  • GSK Investigational Site

    Piteşti, 110283, Romania

  • GSK Investigational Site

    Suceava, 720214, Romania

  • GSK Investigational Site

    Daegu, 42601, South Korea

  • GSK Investigational Site

    Seongnam-si Gyeonggi-do, 13620, South Korea

  • GSK Investigational Site

    Seoul, 03722, South Korea

  • GSK Investigational Site

    Seoul, 138-736, South Korea

  • GSK Investigational Site

    Suwon Kyunggi-do, 443-721, South Korea

  • GSK Investigational Site

    Barcelona, 08023, Spain

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Barcelona, 08907, Spain

  • GSK Investigational Site

    Jaén, 23007, Spain

  • GSK Investigational Site

    Madrid, 28010, Spain

  • GSK Investigational Site

    Madrid, 28034, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, 28223, Spain

  • GSK Investigational Site

    Salamanca, 37007, Spain

  • GSK Investigational Site

    Santander, 39008, Spain

  • GSK Investigational Site

    Valencia, 46009, Spain

  • GSK Investigational Site

    Zaragoza, 50009, Spain

  • GSK Investigational Site

    Changhua, 500, Taiwan

  • GSK Investigational Site

    Tainan, 704, Taiwan

  • GSK Investigational Site

    Taipei, 10002, Taiwan

  • GSK Investigational Site

    Taipei, 11217, Taiwan

  • GSK Investigational Site

    Ankara, 06100, Turkey (Türkiye)

  • GSK Investigational Site

    Istanbul, 34662, Turkey (Türkiye)

  • GSK Investigational Site

    Izmir, 35040, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.